February 2013 Spotlight - Fady Hannah-Shmouni
Fady Hannah-ShmouniYale-New Haven Hospital,
St. Raphael Campus
Yale School of Medicine
2012-15 Internal Medicine Resident. Yale-New Haven Hospital, St. Raphael Campus. Yale School of Medicine.
- 2010-12: Clinical Trainee and Research assistant, Adult Metabolic Diseases Clinic. Division of Endocrinology and Metabolism. Vancouver General Hospital. University of British Columbia
- 2003-09: Doctor of Medicine (MD), School of Medicine, University of Jordan
When did you become interested in research relating to Hypertension?
I became interested in hypertension research during my postgraduate training in endocrinology and metabolism at Vancouver General Hospital. My research focused on adult-onset inborn errors of metabolism, including mitochondrial diseases and disorders of fatty acid oxidation.
Describe your research interest & the research program that you are in?
I am interested in studying the links between mitochondrial dysfunction and disease, including hypertension. Since ISH12, I became more interested in the novel mutations causing aldosterone producing adenomas. I look forward to receiving research exposure in these fields during my training.
How did you know about ISH and its activities?
I came across ISH12 through their online promotional materials. At ISH12, I was fortunate to meet with the members of the New Investigators Network where I felt their strong ambition and dedication to the field of hypertension. I look forward to becoming more involved in their network and initiatives.
What do you consider to be your substantial scientific contribution so far (provide Pubmed PMID if possible)?
My manuscript entitled: Increased Prevalence of Essential Hypertension in Young Adults with High Heteroplasmy levels of the MELAS m.3243A>G Mutation (undergoing peer review), was the first project on hypertension and one that I would regard as the most substantial. In this project, we describe an increased prevalence of hypertension in young adults with higher mutation load in mitochondrial DNA, which has potentially important treatment implications.
Which conference did you first attend & which one did you first present in?
The first conference that I attended was in 2009 organized by the Canadian Academy of Child and Adolescent Psychiatry in Toronto, Ontario. During medical school, I was interested in pursuing a career in child psychiatry, but the subsequent exposure in clinical endocrinology has paved a new and promising adventure for my career.
What upcoming conferences will you be attending and what is the furthest you have traveled for a conference?
American College of Physician (ACP) 2013 in San Francisco and Arteriosclerosis, Thrombosis, Vascular Biology (ATVB) 2013 Scientific Sessions in Orlando. The furthest I have been to was ISH12 in Sydney, Australia.
What is your favourite manuscript from a lab other than your own (provide Pubmed PMID if possible)?
Dr. Lifton's Lab at Yale University:
1.Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PMID: 22848660
2.K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. PMID: 21311022
What entity (i.e. equipment, patient population) is essential to your research?
I am interested in pursuing a career in adult endocrinology, with a focus on adult-onset inborn errors of metabolism and endocrine hypertension. I anticipate working with families with known mutations in the endocrine system and inborn errors of metabolism.
Describe your most memorable (proudest) moment and a challenging instance in your research career so far?
My most memorable moments were establishing a dance initiative since 2007 to help spread health awareness through the arts (www.dancetowardspeace.com) and the completion of medical school in 2009. The main challenge in my research career is finding the time between clinical rotations and research projects.
What area of research do you wish you knew more about?
I would like to broaden my understanding of endocrine hypertension and adult-onset inborn errors of metabolism. The best advice I can give to any investigator is to stay persistent, regardless of the obstacles. Thank you for the opportunity, ISH. I am grateful for your support.